BeOne Medicines Ltd.
▲ 0 upgrades / ▼ 0 downgrades / 3 reiterations from 3 firms
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 8, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Oct 7, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Oct 1, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Sep 10, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Aug 6, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Aug 6, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 6, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Aug 6, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 6, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Aug 6, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Jul 23, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Jul 14, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jul 13, 2026 | Jefferies | upgrade | Hold → Buy | — | 52% |
| Jul 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jul 7, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Jul 1, 2026 | Citizens | reiterate | Market Outperform → Market Outperform | — | 47% |
| Jun 2, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| May 15, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| May 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| May 7, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| May 7, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 7, 2026 | Truist Securities | reiterate | Buy → Buy | — | 54% |
| May 4, 2026 | Wells Fargo | initiate | — → Overweight | — | 54% |
| Mar 27, 2026 | Wolfe Research | initiate | — → Outperform | — | 54% |
| Mar 16, 2026 | Jefferies | downgrade | Buy → Hold | — | 52% |
| Feb 27, 2026 | RBC Capital | maintain | Outperform → Outperform | $425 | 55% |
| Feb 27, 2026 | Truist Securities | maintain | Buy → Buy | $412 | 54% |
| Feb 27, 2026 | Guggenheim | maintain | Buy → Buy | $410 | 52% |
| Feb 27, 2026 | Barclays | maintain | Overweight → Overweight | $405 | 53% |
| Feb 4, 2026 | Barclays | maintain | Overweight → Overweight | $394 | 53% |
| Nov 24, 2025 | Truist Securities | initiate | — → Buy | $400 | 54% |
| Nov 18, 2025 | RBC Capital | maintain | Outperform → Outperform | $408 | 55% |
| Nov 10, 2025 | Citigroup | maintain | Buy → Buy | $405 | 54% |
| Nov 7, 2025 | RBC Capital | maintain | Outperform → Outperform | $395 | 55% |
| Nov 7, 2025 | Citizens | maintain | Market Outperform → Market Outperform | $396 | 47% |
| Oct 20, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $383 | 54% |
| Oct 8, 2025 | JP Morgan | maintain | Overweight → Overweight | $385 | 55% |
| Sep 18, 2025 | Barclays | initiate | — → Overweight | $385 | 53% |
| Aug 7, 2025 | RBC Capital | maintain | Outperform → Outperform | $364 | 55% |
| Aug 7, 2025 | Guggenheim | maintain | Buy → Buy | $365 | 52% |
| Jul 17, 2025 | JP Morgan | maintain | Overweight → Overweight | $345 | 55% |
| Jul 16, 2025 | RBC Capital | maintain | Outperform → Outperform | $349 | 55% |
| Jun 27, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $330 | 54% |
| Jun 27, 2025 | JP Morgan | maintain | Overweight → Overweight | $321 | 55% |
| Jun 27, 2025 | RBC Capital | reiterate | Outperform → Outperform | $311 | 55% |
| May 8, 2025 | RBC Capital | maintain | Outperform → Outperform | $311 | 55% |
| May 8, 2025 | Guggenheim | maintain | Buy → Buy | $350 | 52% |
| Apr 28, 2025 | RBC Capital | reiterate | Outperform → Outperform | $312 | 55% |
| Apr 24, 2025 | TD Securities | reiterate | Buy → Buy | $334 | 53% |
| Apr 21, 2025 | JP Morgan | maintain | Overweight → Overweight | $317 | 55% |
No cross-platform signals in the last 90 days